The 12 Peptides That Quietly Came Off Category 2 in April
⚡ Key Takeaway
On April 23, 2026, twelve peptides were removed from Category 2. Most people missed this entirely — and almost everyone who noticed it got the implications wrong. Coming off Category 2 does NOT mean these peptides are legal to compound. Here’s what it actually means.
On April 15, 2026, HHS Secretary Robert F. Kennedy Jr. confirmed the removal of twelve peptides from FDA Category 2, effective April 23. The announcement generated a wave of excitement across the peptide community — and a tidal wave of misinformation about what it actually changed.
Let’s correct the record.
The 12 Peptides Removed from Category 2
| Peptide | Primary Research Use | PCAC Review | New Status |
|---|---|---|---|
| BPC-157 | Tissue repair, gut healing | July 23, 2026 | Off Cat 2 → PCAC Pending |
| TB-500 | Wound healing, connective tissue | July 23, 2026 | Off Cat 2 → PCAC Pending |
| MOTS-C | Metabolic regulation, energy | July 23, 2026 | Off Cat 2 → PCAC Pending |
| KPV | Anti-inflammatory, wound healing | July 23, 2026 | Off Cat 2 → PCAC Pending |
| Semax | Cognitive enhancement | July 24, 2026 | Off Cat 2 → PCAC Pending |
| Epitalon | Longevity, telomere support | July 24, 2026 | Off Cat 2 → PCAC Pending |
| Emideltide (DSIP) | Sleep induction | July 24, 2026 | Off Cat 2 → PCAC Pending |
| GHK-Cu (injectable) | Skin rejuvenation, wound healing | Before Feb 2027 | Off Cat 2 → Later Review |
| Melanotan II | Tanning, sexual dysfunction | Before Feb 2027 | Off Cat 2 → Later Review |
| PEG-MGF | Muscle growth factor | Before Feb 2027 | Off Cat 2 → Later Review |
| LL-37 (Cathelicidin) | Antimicrobial | Before Feb 2027 | Off Cat 2 → Later Review |
| DiHexa | Cognitive (experimental) | Before Feb 2027 | Off Cat 2 → Later Review |
The Three Things Everyone Confuses
This is the part most coverage gets wrong. There are three completely different regulatory statuses, and they’re constantly conflated:
1. Coming Off Category 2
Category 2 was the FDA’s “restricted” list — substances with unresolved safety or efficacy concerns that could not be compounded. Removal from Category 2 lowers a barrier. It does not create a formal green light. A compounder working with these substances is now operating in a space with reduced restrictions but no formal authorization.
2. Being Added to the 503A Bulks List
The 503A Bulk Drug Substances List contains substances the FDA has affirmatively recognized as appropriate for compounding. Getting on this list requires PCAC review and formal rulemaking. This is what the July 23–24 meeting is about. Being on the list means a licensed 503A pharmacy can compound the substance with an individual prescription, with quality standards applied.
3. FDA Drug Approval
None of these peptides are FDA-approved drugs. Even if BPC-157 gets added to the 503A Bulks List, it won’t have an approved indication, a standardized dosing label, or insurance coverage. It will be legally compoundable — that’s it.
💡 The Distinction That Matters
Off Category 2 = the restriction was removed. On 503A List = formally authorized for compounding. FDA-Approved = approved as a drug with labeled indications. These are three separate statuses. Most peptides currently sit at step one, waiting for step two.
What Stayed on Category 2
Several substances were not removed from Category 2 and remain restricted:
- GHRP-2 — Cortisol and prolactin elevation concerns
- GHRP-6 — Similar safety concerns to GHRP-2
- Ipamorelin — Ongoing litigation and additional review needed
These substances cannot currently be compounded under 503A and have no scheduled PCAC review date.
What This Actually Means for You
If you’re a researcher or biohacker currently sourcing peptides, the Category 2 removal changes nothing about your access today. Research-grade vendors were never restricted by Category 2 — that classification only affected compounding pharmacies.
What it does change is the regulatory trajectory. These twelve peptides are now on a path toward potential legal compounding access. Seven of them face their first real test at the July PCAC meeting. The other five are queued for review before February 2027.
For the definitive explainer on the four regulatory statuses, see our guide: Category 1 vs Category 2 vs 503A Bulks vs FDA-Approved.
Source These Research Peptides
BioPure Peptides
All 12 Category 2 removals available as research-grade compounds. Batch-specific COAs, consistent purity testing across BPC-157, KPV, TB-500, MOTS-C, GHK-Cu, Semax, and Epitalon.
Shop BioPure Peptides →POWER at checkoutMidwest Peptide
Competitive pricing on BPC-157 and MOTS-C with 10% affiliate commission and 30-day cookie.
Shop Midwest Peptide →POWER at checkoutFrequently Asked Questions
No. Removal from Category 2 lowers a restriction but does not formally authorize compounding. These peptides must still be reviewed by the PCAC and added to the 503A Bulks List through formal rulemaking before they can be legally compounded with prescriptions.
Twelve peptides: BPC-157, TB-500, MOTS-C, KPV, GHK-Cu (injectable), Melanotan II, Semax, Epitalon, Emideltide (DSIP), PEG-MGF, LL-37 (Cathelicidin), and DiHexa. Seven go to PCAC review in July 2026; five are scheduled for review before February 2027.
GHRP-2, GHRP-6, and Ipamorelin remain on Category 2 with no scheduled PCAC review date. They cannot be compounded under 503A.
Research-grade peptides were never restricted by Category 2 — that classification only affected compounding pharmacies. Research vendors continue to sell these compounds for legitimate research purposes with third-party testing and certificates of analysis.
Related Articles
Not Sure Which Peptide Is Right for You?
Take our free 60-second quiz and get personalized recommendations based on your goals.
Take the Quiz →